HER-2/neu Oncogene Amplification by Chromogenic in situ Hybridization in 130 Breast Cancers Using Tissue Microarray and Clinical Follow-up Studies.
10.3346/jkms.2004.19.3.390
- Author:
Eundeok CHANG
1
;
Anhi LEE
;
Eunjung LEE
;
Hekyung LEE
;
Okran SHIN
;
Sejeong OH
;
Changsuk KANG
Author Information
1. Department of Clinical Pathology, The Catholic University of Korea, College of Medicine, Seoul, Korea. ejlpath@catholic.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Breast Neoplasms;
Receptor, erbB-2;
In Situ Hybridization;
Immunohistochemistry;
Pro-tein Array Analysis
- MeSH:
Adult;
Aged;
Breast Neoplasms/*genetics/metabolism/mortality;
Disease-Free Survival;
Female;
Follow-Up Studies;
Genes, erbB-2/*genetics;
Human;
Immunohistochemistry;
In Situ Hybridization;
In Situ Hybridization, Fluorescence;
Lymphatic Metastasis;
Middle Aged;
*Oligonucleotide Array Sequence Analysis;
Prognosis;
Protein Array Analysis;
Receptor, erbB-2/biosynthesis;
Sensitivity and Specificity;
Support, Non-U.S. Gov't;
Treatment Outcome
- From:Journal of Korean Medical Science
2004;19(3):390-396
- CountryRepublic of Korea
- Language:English
-
Abstract:
Determining of HER-2/neu oncogene amplification has become clinically important for managing breast cancer. Fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) are currently regarded as the standard methods. Chromogenic in situ hybridization (CISH) was investigated as a new modification with an accurate, sensitive technique. From 1998 to 2002, using CISH and IHC, the amplification and protein expression of the HER-2/neu oncogene were examined using paraffin sections in 130 breast carcinomas and to determine the prognostic role of HER-2/neu for outcome after a follow-up of 24- 64 months. Amplifications by CISH and overexpression by IHC were observed in 28 (22%) and 27 cases (20.8%), respectively. Of the 104 patients, 20 patients (19.2%) with amplification had a shorter disease-free interval (34.9 months vs. 38.0 months in controls) (p=0.372). 15 patients (14.4%) had a disease recurrence, but there is no significant difference between 3 patients amplifying the oncogene and 12 patients without oncogene (20.6 months vs. 19.6 months) (p=0.862). 6 patients (5.8%) of these died. CISH is a useful alternative, particularly for confirming the IHC results. There is no relationship between the early recurrence and the HER-2/neu positive group, but lymph node status was statistically significant.
